Literature DB >> 12109625

Gender- and age-related differences in the endocrine parameters of acromegaly.

A Colao1, G Amato, A M Pedroncelli, R Baldelli, S Grottoli, V Gasco, M Petretta, C Carella, G Pagani, G Tambura, G Lombardi.   

Abstract

Acromegaly is a severe slow-developing disease associated with a poor prognosis for cardiovascular disease. To evaluate the impact of age and gender on the severity of the disease, 151 de novo patients with acromegaly (79 women, 72 men, age range 19-77 yr) were included in this open retrospective multi-center cohort study. Basal GH and IGF-I levels, GH response after glucose load and maximal tumor diameter at MRI were measured in all patients at diagnosis. Fasting GH levels and maximal tumor diameter were similar in women and men, while serum IGF-I levels were lower (664.9+/-24.9 vs 755.9+/-32 microg/l; p=0.02) and GH nadir after glucose load was higher (27.5+/-3.7 vs 18.5+/-2.2 microg/l; p=0.04) in women than in men. In both sexes, patients' age was negatively correlated with basal and nadir GH, IGF-I levels and tumor size; fasting GH levels were positively correlated with IGF-I levels and nadir GH after glucose. No interaction between age and gender was found on biochemical and morphological parameters. At diagnosis, elderly patients with acromegaly have lower GH and IGF-I levels, lower GH nadir after glucose load and smaller adenomas than young patients. Women have lower IGF-I levels but higher GH nadir after glucose load than men. These age and gender differences should be considered to appropriately evaluate the activity of acromegaly throughout a life-span.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12109625     DOI: 10.1007/bf03345496

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984.

Authors:  B A Bengtsson; S Edén; I Ernest; A Odén; B Sjögren
Journal:  Acta Med Scand       Date:  1988

Review 2.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

3.  Effects of estrogen and sex difference on secretion of human growth hormone.

Authors:  A G Frantz; M T Rabkin
Journal:  J Clin Endocrinol Metab       Date:  1965-11       Impact factor: 5.958

4.  Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.

Authors:  P Burman; A G Johansson; A Siegbahn; B Vessby; F A Karlsson
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

Review 5.  Current treatment guidelines for acromegaly.

Authors:  S Melmed; I Jackson; D Kleinberg; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

6.  Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion.

Authors:  L M Winer; M A Shaw; G Baumann
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

7.  Sex difference in the relation between sellar volume and basal and GH-releasing hormone stimulated GH in acromegaly.

Authors:  A E Smals; G F Pieters; A G Smals; P W Kloppenborg
Journal:  Acta Endocrinol (Copenh)       Date:  1988-03

8.  Determinants of clinical outcome and survival in acromegaly.

Authors:  C Rajasoorya; I M Holdaway; P Wrightson; D J Scott; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-07       Impact factor: 3.478

9.  The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.

Authors:  A J van der Lely; A G Harris; S W Lamberts
Journal:  Clin Endocrinol (Oxf)       Date:  1992-08       Impact factor: 3.478

10.  Growth hormone: metabolic clearance rates, integrated concentrations, and production rates in normal adults and the effect of prednisone.

Authors:  R G Thompson; A Rodriguez; A Kowarski; R M Blizzard
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

View more
  13 in total

Review 1.  Improving immunity in the elderly: current and future lessons from nonhuman primate models.

Authors:  Christine Meyer; Amelia Kerns; Kristen Haberthur; Ilhem Messaoudi
Journal:  Age (Dordr)       Date:  2011-12-20

Review 2.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

4.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

5.  Diagnosis and management of acromegaly: the patient's perspective.

Authors:  Ilonka Kreitschmann-Andermahr; Sonja Siegel; Bernadette Kleist; Johannes Kohlmann; Daniel Starz; Rolf Buslei; Maria Koltowska-Häggström; Christian J Strasburger; Michael Buchfelder
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

Review 6.  Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management.

Authors:  Mehdi Zeinalizadeh; Zohreh Habibi; Juan C Fernandez-Miranda; Paul A Gardner; Steven P Hodak; Sue M Challinor
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

7.  A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients.

Authors:  A Colao; R Pivonello; L Spinelli; M Galderisi; R S Auriemma; M Galdiero; G Vitale; M De Leo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

8.  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Authors:  Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  Endocrine       Date:  2019-11-01       Impact factor: 3.633

9.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05

Review 10.  [Acromegaly features in the aging population].

Authors:  Nadia Anoun; Hanan El Ouahabi
Journal:  Pan Afr Med J       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.